Reports: Thursday, July 30, 2026, ~6:30 a.m. ET (release) / 8:30 a.m. ET (call)
CI shares enter the print near cycle highs — around $298 as of July 29, having rallied from the high-$270s in early July to briefly touch ~$304 on July 13-14 after Bernstein lifted its price target to $381 on a "positive outlook," before pulling back with the broader managed-care group in the second half of July. The stock is up modestly year-to-date and has outperformed Humana and tracked roughly with Elevance, though it trails UnitedHealth's sharp turnaround rally.
Wall Street is looking for adjusted EPS of ~$7.58–$7.60 on revenue of roughly $70–71 billion, which would represent about 5% year-over-year EPS growth. Notably, this consensus lines up almost exactly with management's own guidance cadence: on the Q1 call, CFO Ann Dennison said the company expects second-quarter adjusted EPS to be approximately 25% of the full-year outlook — implying ~$7.59 against the current full-year floor of at least $30.35. That tight alignment means the bar is fairly "clean" — a print in the high-$7.50s/low-$7.60s should be viewed as in-line, and the more important signal will be commentary on the medical care ratio (MCR) trajectory and any change to full-year guidance.
Q1 2026 was strong across the board: total revenue of $68.5 billion and adjusted EPS of $7.79, up 16% year-over-year, prompting management to raise full-year adjusted EPS guidance to at least $30.35 (from $30.25) and raise the Cigna Healthcare pre-tax earnings outlook to at least $4.525 billion. Cigna Healthcare's segment earnings grew 18% and the Q1 MCR came in at 79.8%, well below the roughly-81% level guided, helped by low flu/respiratory volumes, weather-related care deferrals, and a richer mix of bronze-plan individual-exchange members early in the year. Evernorth's Specialty and Care Services business grew pre-tax earnings 20%, while Pharmacy Benefit Services earnings fell 28% (~$150 million), reflecting previously flagged large client renewals and investment ramp into the new "Signature" rebate-free pharmacy model.
Three structural developments from Q1 remain live into this print and are worth tracking for updates:
Cigna Healthcare (Q2 MCR is the single most important number). Management guided Q2 MCR to be "slightly above the high end of the full-year range" of 83.7%–84.7%, i.e., roughly 85%+, driven by normal seasonality (steeper now that the flatter-seasonality Medicare book has been divested to HCSC), a richer mix of bronze-plan ACA members reversing through the year, and weather/flu timing benefits from Q1 unwinding. Full-year MCR guidance was reiterated as unchanged. The key question for the call: does the sequential step-up land in line with that guide, and does management reiterate that underlying cost trend remains "elevated but not accelerating" — commentary that would support continued conservatism/upside optionality, similar to what peers have flagged this cycle.
Evernorth. Look for continued strength in Specialty and Care Services (management guided to the high end of its 8–12% secular growth range, helped by biosimilar/specialty-generic adoption, generic Revlimid, and the Shields Health Solutions investment) offsetting a still-declining Pharmacy Benefit Services segment as large client renewal headwinds and Signature investment spending continue to weigh on that business through 2026.
Capital deployment. Watch commentary on the debt-to-capitalization ratio (42.3% at Q1, expected to improve by year-end) and share repurchase pace, as well as any early details on capital freed up from the eviCore review or exchange exit ahead of the company's planned Investor Day in September 2026.
This is a mixed managed-care earnings season, and CI's read-through peers have set a wide range of outcomes:
The broader tape suggests investors are rewarding evidence of decelerating medical cost trend and clear, credible guidance raises, and punishing "good-not-great" prints or unchanged outlooks even when headline numbers beat. Given CI's mix (Evernorth/PBM-heavy, smaller pure insurance-risk exposure after the Medicare divestiture to HCSC), it is somewhat insulated from the Medicare Advantage/Medicaid cost pressures driving the divergence between UNH, ELV, and HUM, but the market's reaction function this quarter has clearly been about the trajectory and credibility of full-year guidance, not just the quarterly beat.
Also relevant: the ACA marketplace continues to face disruption following the expiration of enhanced premium tax credits at the end of 2025, which is driving materially higher premiums and enrollment uncertainty for 2026 exchange business — the same dynamic that is informing Cigna's decision to exit the individual exchange market after this year. Separately, the Trump administration this week announced it will end a Medicare Part D premium subsidy program starting in 2027, adding another data point to the shifting government-program backdrop, though this affects Medicare Part D (a business Cigna largely exited via the HCSC transaction) more than Cigna's current core book.
Expectations are calibrated tightly to management's own guidance cadence (~$7.58–$7.60 EPS), so an in-line beat is unlikely to move the stock much on its own. The swing factors are (1) the Cigna Healthcare MCR trajectory and cost-trend commentary relative to a sector that has just shown it will reward credible guidance raises (UNH) and punish "good but not good enough" outlooks (ELV, HUM), and (2) any incremental news on the eviCore review, ACA exchange exit economics, or capital deployment plans under new CEO Brian Evanko's first quarter at the helm.